Cargando…

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

AIMS: To evaluate the efficacy and safety of extended dosing with mipomersen in patients with familial hypercholesterolaemia (HC) taking maximally tolerated lipid-lowering therapy. METHODS AND RESULTS: A planned interim analysis of an ongoing, open-label extension trial in patients (n = 141) with fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santos, Raul D., Duell, P. Barton, East, Cara, Guyton, John R., Moriarty, Patrick M., Chin, Wai, Mittleman, Robert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4344956/ https://www.ncbi.nlm.nih.gov/pubmed/24366918 http://dx.doi.org/10.1093/eurheartj/eht549

Ejemplares similares

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia
por: Bell, Damon A, et al.
Publicado: (2012)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
por: Goldman, Robert, et al.
Publicado: (2018)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study
por: Nash, Peter, et al.
Publicado: (2020)

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
por: Smith, Edward C., et al.
Publicado: (2020)

Apolipoprotein B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis C
por: Schaefer, Esperance A K, et al.
Publicado: (2016)

Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
por: Chambergo-Michilot, Diego, et al.
Publicado: (2022)

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia
por: Parhofer, Klaus G
Publicado: (2012)

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
por: Harvey, Philip D, et al.
Publicado: (2018)

The Effect of Mipomersen in the Management of Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis of Clinical Trials
por: Astaneh, Behrooz, et al.
Publicado: (2021)

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy
por: McGowan, Mary P., et al.
Publicado: (2012)

Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro(®)): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
por: Geary, Richard S., et al.
Publicado: (2015)

Hypercholesterolaemia in a vegan.
por: Duggan, B., et al.
Publicado: (1997)

Nutraceuticals in hypercholesterolaemia: an overview
por: Santini, Antonello, et al.
Publicado: (2016)

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up
por: Papp, K.A., et al.
Publicado: (2021)

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022)

The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
por: Frank, Samuel, et al.
Publicado: (2022)

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study
por: Langslet, Gisle, et al.
Publicado: (2020)

Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers
por: Flaim, JoAnn D., et al.
Publicado: (2014)

Efficacy of dimethyl fumarate in Japanese multiple sclerosis patients: interim analysis of randomized, double-blind APEX study and its open-label extension
por: Kondo, T, et al.
Publicado: (2019)

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study
por: Knupp, Kelly G., et al.
Publicado: (2022)

The genetics and screening of familial hypercholesterolaemia
por: Henderson, Raymond, et al.
Publicado: (2016)

Genetic Architecture of Familial Hypercholesterolaemia
por: Sharifi, Mahtab, et al.
Publicado: (2017)

Tendon xanthomas in familial hypercholesterolaemia
por: Bharath, Gopinath, et al.
Publicado: (2020)

Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia
por: Imanishi, Yasuo, et al.
Publicado: (2020)

Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK
por: Kerr, Marion, et al.
Publicado: (2017)

Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan
por: Sonoyama, Takuhiro, et al.
Publicado: (2023)

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis
por: Thompson, Richard J., et al.
Publicado: (2023)

Hypercholesterolaemia – practical information for non-specialists
por: Soran, Handrean, et al.
Publicado: (2017)

Cardiovascular risk stratification in familial hypercholesterolaemia
por: Sharifi, Mahtab, et al.
Publicado: (2016)

Serum paraoxonase activity in familial hypercholesterolaemia
por: Kotani, Kazuhiko, et al.
Publicado: (2023)

Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension
por: Aman, Michael G., et al.
Publicado: (2017)

Long‐term safety of brodalumab in Japanese patients with plaque psoriasis: An open‐label extension study
por: Yamaguchi, Yukie, et al.
Publicado: (2020)

Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study
por: Iyo, Masaomi, et al.
Publicado: (2021)

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
por: Ben-Omran, Tawfeg, et al.
Publicado: (2019)

An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023)

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Alexander, Barbara D, et al.
Publicado: (2020)

Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study
por: Ai, Jingwen, et al.
Publicado: (2022)

Safety and Effectiveness of Blonanserin in Chinese Patients with Schizophrenia: An Interim Analysis of a 12-Week Open-Label Prospective Multi-Center Post-marketing Surveillance
por: Wu, Haishan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_11sk1hvjlju63u03k7p6v11rd0